IQVIA Holdings (IQV) Earnings Date & Reports

Key Takeaways

• Adjusted diluted EPS came in at $3.15, topping the Zacks Consensus Estimate of $3.02 by 4.3% and the FactSet consensus of $3.03.
• Revenue reached $4.37 billion, up 8.7% year-over-year and above analyst expectations of approximately $4.30 billion.
• R&D Solutions net new bookings surged to a record $3.15 billion, up 19% year-over-year, producing a 1.22x book-to-bill ratio.
• Full-year 2026 guidance was raised across all key metrics, with the new adjusted EPS midpoint of $12.90 surpassing the prior high end of $12.95.
• Shares jumped more than 8% in premarket trading, reflecting broad investor enthusiasm for the beat-and-raise quarter.
• Free cash flow grew 23% year-over-year to $360 million, supported by a 26% increase in operating cash flow.

Earnings Context and Why It Matters

IQVIA Holdings is the world's largest contract research organization (CRO), providing clinical trial management, data analytics, and commercial outsourcing services to the pharmaceutical and biotechnology industries. Its quarterly results serve as a barometer for global drug development spending and the health of the broader life sciences outsourcing market. Coming off a strong first quarter, this Q2 report was closely watched for signs of sustained demand across both large pharmaceutical and emerging biopharma (EBP) customers. With the company's AI-powered tools gaining traction among top-tier drugmakers — 19 of the top 20 pharmaceutical companies now deploy IQVIA AI solutions — the quarter offered a real-world test of whether AI-driven differentiation is translating into measurable financial momentum.

Reported Results

IQVIA reported second-quarter 2026 revenue of $4.368 billion, an increase of 8.7% on a reported basis (8.5% in constant currency) compared to the year-ago period. The figure exceeded the Zacks Consensus Estimate of $4.29 billion and the FactSet consensus of approximately $4.30 billion by roughly 1.6%. Organic revenue growth accelerated to 6%, approximately three times the pace recorded in the prior-year quarter, while acquisitions contributed an additional 2.5 percentage points to the top line.

By segment, Research & Development Solutions (R&DS) generated $2.575 billion in revenue, up 8.8% on a reported basis. Excluding reimbursed expenses, R&DS revenue grew 6.7%. Net new bookings for the segment reached a record $3.15 billion, a 19% year-over-year jump, driving a book-to-bill ratio of 1.22x. The contracted backlog stood at $34.2 billion as of June 30, 2026, with approximately $9.2 billion expected to convert to revenue in the next twelve months — a 7.5% increase over the comparable forward metric from a year ago.

Commercial Solutions posted revenue of $1.793 billion, rising 8.6% on a reported basis (8.4% at constant currency). The segment benefited from double-digit growth in patient solutions and commercial engagement services, together with high-single-digit organic growth in analytics and consulting.

On the profitability side, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 9.2% to $994 million, with the adjusted EBITDA margin holding at approximately 23.2%. Adjusted diluted EPS climbed 12.1% year-over-year to $3.15, comfortably above the consensus range of $3.02 to $3.04. On a GAAP (Generally Accepted Accounting Principles) basis, net income was $256 million, or $1.53 per diluted share.

Operating cash flow of $558 million represented a 26% increase from the prior-year quarter, and free cash flow of $360 million grew 23%. The company repurchased $398 million in shares during the quarter, with approximately $2.8 billion remaining under its current authorization.

AI Screener

Identifying stocks with strong earnings momentum can be time-consuming, but Tickeron's AI Screener streamlines that process. The AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamental metrics, trend signals, volatility indicators, and AI-driven analytics. Users can scan thousands of equities using customizable filters — including industry classification, market capitalization, technical indicators, price patterns, and performance benchmarks — to pinpoint trade ideas, breakout candidates, and emerging market opportunities more efficiently than manual screening. Explore how the AI Screener can enhance your market research workflow.

Market Reaction and Investor Sentiment

IQVIA shares surged more than 8% in premarket trading on July 28, climbing to roughly $231, within striking distance of the stock's 52-week high of $247.72. The rally reflected a broad endorsement of the quarter's quality: not only did the company beat on both revenue and earnings, but the magnitude and composition of the beat — driven by operating performance rather than one-time items — reinforced confidence in the durability of the underlying growth trend. The record R&DS bookings figure and the raised full-year guidance were particularly well-received, as they point to sustained momentum heading into the second half of 2026 and beyond. Heading into the release, shares had been down approximately 5% year-to-date, trailing the S&P 500, which made the post-earnings pop a notable reversal in relative performance.

Forward Outlook and Key Factors to Monitor

IQVIA raised its full-year 2026 revenue guidance to a range of $17.275 billion to $17.475 billion, up from the prior range of $17.15 billion to $17.35 billion. The new midpoint implies approximately 6.5% reported growth, supported by stronger organic growth and a higher contribution from acquisitions — now expected to add roughly 200 basis points, up from 150 basis points previously.

Full-year adjusted EBITDA guidance rose to $4.0 billion to $4.05 billion, and adjusted diluted EPS guidance moved to $12.80 to $13.00, compared with the prior outlook of $12.65 to $12.95. For the third quarter specifically, management guided to revenue of $4.315 billion to $4.390 billion and adjusted diluted EPS of $3.19 to $3.29.

Investors should monitor several forward-looking indicators. First, the trajectory of organic revenue growth — which accelerated meaningfully in Q2 — will be a key test of whether the strengthening demand environment is sustainable. Second, the conversion rate of the $34.2 billion backlog into recognized revenue will provide visibility into 2027 performance. Third, AI adoption metrics bear watching: with 294 AI agents deployed across 90 use cases and growing co-development agreements with large pharmaceutical partners, AI-driven productivity gains could increasingly influence margin performance.

On the cost side, pass-through revenue growth — which carries no profit margin — remains a modest drag on reported margins, partially offsetting operational efficiency gains. Foreign exchange assumptions have also shifted, with the company now expecting only a 20-basis-point tailwind compared to 100 basis points previously. Finally, IQVIA plans to hold an investor day on December 2, 2026, which may provide a longer-term strategic framework and updated multi-year financial targets. With the outsourcing market expected to keep expanding through 2027 and into 2028 — supported by AI adoption, stronger EBP funding, and accelerating new drug launches — IQVIA's positioning at the intersection of clinical research and data analytics places it near the center of several durable secular trends in healthcare.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations